Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5805153 | 0.91 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL2798824 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL27572033 | 0.87 | TP53 (0.54) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL5090319 | 0.86 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL4312600 | 0.86 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL25736671 | 0.86 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL9407535 | 0.86 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL9525952 | 0.84 | KDM4E (0.45) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3657533 | 0.84 | MT-CO2 (0.46) | MEN1KMT2ACYP3A4F2SSTR4 | |
| SCHEMBL19317380 | 0.84 | F2 (0.50) | SMN1; SMN2MEN1KMT2ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624061-A | Production process of oxaagoli sodium | 宣城美诺华药业有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-109956906-B | Preparation method of key intermediate of oxalagogri | 奥锐特药业股份有限公司 | 2021-01-29 | — | — | CN | claimed |
| CN-121298990-A | Detection method of Boc-D-phenylglycinol isomer | 金陵药业股份有限公司 | 2026-01-09 | — | — | CN | disclosed |
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-20250084042-A1 | Elagolix Sodium Compositions and Processes | ABBVIE INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4031533-B1 | PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2025-01-01 | — | — | EP | disclosed |
| CN-118580178-A | Method for synthesizing C-4 alkylpyridine by taking alcohol as alkylating reagent | 陕西师范大学 | 2024-09-03 | — | — | CN | disclosed |
| CN-118459410-A | Synthesis method of byproducts in oxaragroli intermediate synthesis route | 诚达药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-4373814-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117624061-A | Production process of oxaagoli sodium | 宣城美诺华药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-12-12 | — | — | US | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-1012166-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-28 | — | — | EP | disclosed |
| EP-1009758-A1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-21 | — | — | EP | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999011658-A1 | META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
| WO-1999011657-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
| US-5864045-A | Heterocyclic substituted piperazinone derivatives | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5840726-A | Heterocyclic substituted piperazinone derivatives | HOECHST MARION ROUSSEL INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0610943-A1 | Pyridinium derivatives useful as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1994-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | SMN1; SMN2 3396/4885MEN1 3749/4885KMT2A 3265/4885 |
| US-20250084042-A1 | Elagolix Sodium Compositions and Processes | ELOVL5, ELOC, ELOVL3 | SMN1; SMN2 2602/4885MEN1 1646/4885KMT2A 2023/4885 |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | ELP1, BPNT1, EPX | SMN1; SMN2 3833/4885MEN1 3852/4885KMT2A 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.